Last reviewed · How we verify

NCT06027333

Self-efficacy and Well-being of Patients With Fibrotic Interstitial Lung Disease

Status unknown Last updated 13 March 2024
What this trial tests

trial testing inpatient rehabilitation in Interstitial Lung Disease in 80 participants. Status unknown.

Timeline
8 November 2023
Primary endpoint
30 August 2024
30 August 2024

Quick facts

Lead sponsorBerner Reha Zentrum AG
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment80
Start date8 November 2023
Primary completion30 August 2024
Estimated completion30 August 2024
Sites2 locations across Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

Berner Reha Zentrum AG

Who can join

18 and older, any sex, with Interstitial Lung Disease or Fibrotic Lung Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with fibrotic insterstitial lung disease (ILD) participating in inpatient rehabilitation or in outpatient pulmonary care will be invited to participate in this observational study. Patients will fill out questionnaire regarding quality of life and symptoms at baseline and follow-up (at the end of rehabilitation or after the second outpatient ILD consultation). Additionally, clinical data obtained in clinical routine or for the IIP registry will be used for this project. The aim is to assess changes in self-efficacy and quality of life over time and to establish a control cohort for a later feasibility study on a educational and self-management intervention (currently in planning).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of inpatient rehabilitation

Trials testing the same drug.

Other recruiting trials for Interstitial Lung Disease

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06027333.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing